JP2007503443A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007503443A5 JP2007503443A5 JP2006524755A JP2006524755A JP2007503443A5 JP 2007503443 A5 JP2007503443 A5 JP 2007503443A5 JP 2006524755 A JP2006524755 A JP 2006524755A JP 2006524755 A JP2006524755 A JP 2006524755A JP 2007503443 A5 JP2007503443 A5 JP 2007503443A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridyl
- xanthine
- alkyl
- dipropyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 119
- 229940075420 xanthine Drugs 0.000 claims 62
- 150000001875 compounds Chemical class 0.000 claims 51
- -1 which is optionally Chemical group 0.000 claims 46
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 36
- 239000001257 hydrogen Substances 0.000 claims 32
- 229910052739 hydrogen Inorganic materials 0.000 claims 32
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 30
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 20
- 125000005843 halogen group Chemical group 0.000 claims 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 15
- 150000002431 hydrogen Chemical group 0.000 claims 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims 14
- 125000000623 heterocyclic group Chemical group 0.000 claims 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 14
- 125000001072 heteroaryl group Chemical group 0.000 claims 13
- 125000001424 substituent group Chemical group 0.000 claims 13
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 12
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 11
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 10
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 10
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 10
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 10
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 8
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 8
- 125000000304 alkynyl group Chemical group 0.000 claims 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 5
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 4
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 3
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 3
- 150000001412 amines Chemical class 0.000 claims 3
- 125000002785 azepinyl group Chemical group 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 claims 3
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- 125000006178 methyl benzyl group Chemical group 0.000 claims 3
- 125000002757 morpholinyl group Chemical group 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 3
- 125000004193 piperazinyl group Chemical group 0.000 claims 3
- 125000005936 piperidyl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000006413 ring segment Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 3
- MDNORVBNPKBWBW-UHFFFAOYSA-N 1,3-diethyl-8-[6-(2-pyrrolidin-1-ylethylamino)pyridin-3-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1C(C=N1)=CC=C1NCCN1CCCC1 MDNORVBNPKBWBW-UHFFFAOYSA-N 0.000 claims 2
- WPHTUXVYLNYAPA-UHFFFAOYSA-N 1,3-diethyl-8-[6-(pyridin-2-ylmethylamino)pyridin-3-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1C(C=N1)=CC=C1NCC1=CC=CC=N1 WPHTUXVYLNYAPA-UHFFFAOYSA-N 0.000 claims 2
- ACPCSLMZOHRHCS-UHFFFAOYSA-N 1,3-diethyl-8-[6-(pyridin-3-ylmethylamino)pyridin-3-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1C(C=N1)=CC=C1NCC1=CC=CN=C1 ACPCSLMZOHRHCS-UHFFFAOYSA-N 0.000 claims 2
- AMLDMLKJJSTZMK-UHFFFAOYSA-N 1,3-diethyl-8-[6-[(3-methoxyphenyl)methylamino]pyridin-3-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1C(C=N1)=CC=C1NCC1=CC=CC(OC)=C1 AMLDMLKJJSTZMK-UHFFFAOYSA-N 0.000 claims 2
- WOKWGMFNGCZRJL-UHFFFAOYSA-N 1,3-dimethyl-8-[6-(methylamino)pyridin-3-yl]-7h-purine-2,6-dione Chemical compound C1=NC(NC)=CC=C1C(N1)=NC2=C1C(=O)N(C)C(=O)N2C WOKWGMFNGCZRJL-UHFFFAOYSA-N 0.000 claims 2
- ZPFNEXUPYQUHEN-UHFFFAOYSA-N 1,3-dipropyl-8-(6-pyrrolidin-1-ylpyridin-3-yl)-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1N1CCCC1 ZPFNEXUPYQUHEN-UHFFFAOYSA-N 0.000 claims 2
- YXKJPXVMZWGIBI-UHFFFAOYSA-N 1,3-dipropyl-8-[6-(2-pyridin-2-ylethylamino)pyridin-3-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1NCCC1=CC=CC=N1 YXKJPXVMZWGIBI-UHFFFAOYSA-N 0.000 claims 2
- RTYAAMZBWVNQHX-UHFFFAOYSA-N 1-[5-(1,3-diethyl-2,6-dioxo-7h-purin-8-yl)pyridin-2-yl]-1-(2-methoxyethyl)-3-pyridin-4-ylurea Chemical compound N1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1C(C=N1)=CC=C1N(CCOC)C(=O)NC1=CC=NC=C1 RTYAAMZBWVNQHX-UHFFFAOYSA-N 0.000 claims 2
- LFXCYVITBNVTHL-UHFFFAOYSA-N 8-(6-chloropyridin-3-yl)-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(Cl)N=C1 LFXCYVITBNVTHL-UHFFFAOYSA-N 0.000 claims 2
- OJWDYRZKBKCUAP-UHFFFAOYSA-N 8-(6-morpholin-4-ylpyridin-3-yl)-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1N1CCOCC1 OJWDYRZKBKCUAP-UHFFFAOYSA-N 0.000 claims 2
- YITUHJOCTFWXRO-UHFFFAOYSA-N 8-(6-piperazin-1-ylpyridin-3-yl)-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1N1CCNCC1 YITUHJOCTFWXRO-UHFFFAOYSA-N 0.000 claims 2
- CCOGRGCHXAXCLY-UHFFFAOYSA-N 8-[6-(1-hydroxypropan-2-ylamino)pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(NC(C)CO)N=C1 CCOGRGCHXAXCLY-UHFFFAOYSA-N 0.000 claims 2
- YEYAJHKHEQLJSU-UHFFFAOYSA-N 8-[6-(2,2-dimethoxyethylamino)pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(NCC(OC)OC)N=C1 YEYAJHKHEQLJSU-UHFFFAOYSA-N 0.000 claims 2
- DSEIFWOSOXXVCQ-UHFFFAOYSA-N 8-[6-(2-hydroxyethylamino)pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(NCCO)N=C1 DSEIFWOSOXXVCQ-UHFFFAOYSA-N 0.000 claims 2
- LUNHWMIOHDKVMI-UHFFFAOYSA-N 8-[6-(2-hydroxypropylamino)pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(NCC(C)O)N=C1 LUNHWMIOHDKVMI-UHFFFAOYSA-N 0.000 claims 2
- JUYSXFPGBMZVFU-UHFFFAOYSA-N 8-[6-(4-acetylpiperazin-1-yl)pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1N1CCN(C(C)=O)CC1 JUYSXFPGBMZVFU-UHFFFAOYSA-N 0.000 claims 2
- XTETXCDXUFUPRO-UHFFFAOYSA-N 8-[6-(4-methyl-1,4-diazepan-1-yl)pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1N1CCCN(C)CC1 XTETXCDXUFUPRO-UHFFFAOYSA-N 0.000 claims 2
- KVBOVZQWQICWQI-UHFFFAOYSA-N 8-[6-(dimethylamino)pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(N(C)C)N=C1 KVBOVZQWQICWQI-UHFFFAOYSA-N 0.000 claims 2
- ZRJNXCPEVPTJAO-UHFFFAOYSA-N 8-[6-(ethylamino)pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(NCC)N=C1 ZRJNXCPEVPTJAO-UHFFFAOYSA-N 0.000 claims 2
- UZVULRPRIUSGOU-UHFFFAOYSA-N 8-[6-(methylamino)pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(NC)N=C1 UZVULRPRIUSGOU-UHFFFAOYSA-N 0.000 claims 2
- KUDCJUNZZJSTFH-UHFFFAOYSA-N 8-[6-[[4-(aminomethyl)phenyl]methylamino]pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1NCC1=CC=C(CN)C=C1 KUDCJUNZZJSTFH-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- GOKQVWBBFBOYQL-UHFFFAOYSA-N n-[2-[[5-(2,6-dioxo-1,3-dipropyl-7h-purin-8-yl)pyridin-2-yl]amino]ethyl]acetamide Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(NCCNC(C)=O)N=C1 GOKQVWBBFBOYQL-UHFFFAOYSA-N 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000005592 polycycloalkyl group Polymers 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000004306 triazinyl group Chemical group 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- 125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical group 0.000 claims 1
- IFLFELZCFXQLGN-UHFFFAOYSA-N 1,3-bis(cyclopropylmethyl)-8-[6-(methylamino)pyridin-3-yl]-7h-purine-2,6-dione Chemical compound C1=NC(NC)=CC=C1C(N1)=NC2=C1C(=O)N(CC1CC1)C(=O)N2CC1CC1 IFLFELZCFXQLGN-UHFFFAOYSA-N 0.000 claims 1
- DFKVQPMXXSMIRH-UHFFFAOYSA-N 1,3-diethyl-8-(6-hydrazinylpyridin-3-yl)-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1C1=CC=C(NN)N=C1 DFKVQPMXXSMIRH-UHFFFAOYSA-N 0.000 claims 1
- FXFOPWFQZYTBGQ-UHFFFAOYSA-N 1,3-diethyl-8-(6-piperazin-1-ylpyridin-3-yl)-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1C(C=N1)=CC=C1N1CCNCC1 FXFOPWFQZYTBGQ-UHFFFAOYSA-N 0.000 claims 1
- JDAIIBVBMKHMRV-UHFFFAOYSA-N 1,3-diethyl-8-(6-pyrrolidin-1-ylpyridin-3-yl)-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1C(C=N1)=CC=C1N1CCCC1 JDAIIBVBMKHMRV-UHFFFAOYSA-N 0.000 claims 1
- YEVKMLIRPXIILD-UHFFFAOYSA-N 1,3-diethyl-8-[6-(2-methoxyethylamino)pyridin-3-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1C1=CC=C(NCCOC)N=C1 YEVKMLIRPXIILD-UHFFFAOYSA-N 0.000 claims 1
- KDVJCOVCCHYLAN-UHFFFAOYSA-N 1,3-diethyl-8-[6-(2-pyridin-2-ylethylamino)pyridin-3-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1C(C=N1)=CC=C1NCCC1=CC=CC=N1 KDVJCOVCCHYLAN-UHFFFAOYSA-N 0.000 claims 1
- FNXANIKDBCUJFU-UHFFFAOYSA-N 1,3-diethyl-8-[6-(2-pyridin-3-ylethylamino)pyridin-3-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1C(C=N1)=CC=C1NCCC1=CC=CN=C1 FNXANIKDBCUJFU-UHFFFAOYSA-N 0.000 claims 1
- ZAKSGVNUQDLKJI-UHFFFAOYSA-N 1,3-diethyl-8-[6-(4-pyridin-2-ylpiperazin-1-yl)pyridin-3-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1C(C=N1)=CC=C1N(CC1)CCN1C1=CC=CC=N1 ZAKSGVNUQDLKJI-UHFFFAOYSA-N 0.000 claims 1
- GFQZJFIWUWHPKK-UHFFFAOYSA-N 1,3-diethyl-8-[6-(ethylamino)pyridin-3-yl]-7h-purine-2,6-dione Chemical compound C1=NC(NCC)=CC=C1C(N1)=NC2=C1C(=O)N(CC)C(=O)N2CC GFQZJFIWUWHPKK-UHFFFAOYSA-N 0.000 claims 1
- SDOISGYXPAHLCT-UHFFFAOYSA-N 1,3-diethyl-8-[6-(methylamino)pyridin-3-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1C1=CC=C(NC)N=C1 SDOISGYXPAHLCT-UHFFFAOYSA-N 0.000 claims 1
- BFZQIWAAJMDUHH-UHFFFAOYSA-N 1,3-dipropyl-8-[6-(2-pyridin-3-ylethylamino)pyridin-3-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1NCCC1=CC=CN=C1 BFZQIWAAJMDUHH-UHFFFAOYSA-N 0.000 claims 1
- DHFBNIRKDALHDN-UHFFFAOYSA-N 1,3-dipropyl-8-[6-(4-pyridin-2-ylpiperazin-1-yl)pyridin-3-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1N(CC1)CCN1C1=CC=CC=N1 DHFBNIRKDALHDN-UHFFFAOYSA-N 0.000 claims 1
- PQUQIZKVWHSREO-UHFFFAOYSA-N 1,3-dipropyl-8-[6-(propylamino)pyridin-3-yl]-7h-purine-2,6-dione Chemical compound C1=NC(NCCC)=CC=C1C(N1)=NC2=C1C(=O)N(CCC)C(=O)N2CCC PQUQIZKVWHSREO-UHFFFAOYSA-N 0.000 claims 1
- SDNNLUOKPWUNIE-UHFFFAOYSA-N 1,3-dipropyl-8-[6-(pyridin-2-ylmethylamino)pyridin-3-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1NCC1=CC=CC=N1 SDNNLUOKPWUNIE-UHFFFAOYSA-N 0.000 claims 1
- VHBNSKSUZNEIKN-UHFFFAOYSA-N 1,3-dipropyl-8-[6-(pyridin-3-ylmethylamino)pyridin-3-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1NCC1=CC=CN=C1 VHBNSKSUZNEIKN-UHFFFAOYSA-N 0.000 claims 1
- NJDFVPQFAZZGCD-UHFFFAOYSA-N 1,3-dipropyl-8-[6-(pyridin-4-ylamino)pyridin-3-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1NC1=CC=NC=C1 NJDFVPQFAZZGCD-UHFFFAOYSA-N 0.000 claims 1
- UKRMBINNGLSNTR-UHFFFAOYSA-N 1,3-dipropyl-8-[6-(thiophen-2-ylmethylamino)pyridin-3-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1NCC1=CC=CS1 UKRMBINNGLSNTR-UHFFFAOYSA-N 0.000 claims 1
- URSMMEIGUOXILT-UHFFFAOYSA-N 1-(cyclopropylmethyl)-3-ethyl-8-[6-(methylamino)pyridin-3-yl]-7h-purine-2,6-dione Chemical compound O=C1N(CC)C=2N=C(C=3C=NC(NC)=CC=3)NC=2C(=O)N1CC1CC1 URSMMEIGUOXILT-UHFFFAOYSA-N 0.000 claims 1
- KQUAXDUORCKXRU-UHFFFAOYSA-N 1-cyclopropyl-3-ethyl-8-[6-(methylamino)pyridin-3-yl]-7h-purine-2,6-dione Chemical compound O=C1N(CC)C=2N=C(C=3C=NC(NC)=CC=3)NC=2C(=O)N1C1CC1 KQUAXDUORCKXRU-UHFFFAOYSA-N 0.000 claims 1
- HXKWXZFMPSMNLP-UHFFFAOYSA-N 1-cyclopropyl-8-[6-(2-methoxyethylamino)pyridin-3-yl]-3-propyl-7h-purine-2,6-dione Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(NCCOC)=CC=3)NC=2C(=O)N1C1CC1 HXKWXZFMPSMNLP-UHFFFAOYSA-N 0.000 claims 1
- CPAFOHDUXCUDBQ-UHFFFAOYSA-N 1-cyclopropyl-8-[6-(methylamino)pyridin-3-yl]-3-propyl-7h-purine-2,6-dione Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(NC)=CC=3)NC=2C(=O)N1C1CC1 CPAFOHDUXCUDBQ-UHFFFAOYSA-N 0.000 claims 1
- OOQFDAKIXHLFBN-UHFFFAOYSA-N 3-(2-methoxy-2-phenylethyl)-8-(6-piperazin-1-ylpyridin-3-yl)-1-propyl-7h-purine-2,6-dione Chemical compound C1=2N=C(C=3C=NC(=CC=3)N3CCNCC3)NC=2C(=O)N(CCC)C(=O)N1CC(OC)C1=CC=CC=C1 OOQFDAKIXHLFBN-UHFFFAOYSA-N 0.000 claims 1
- QRAJFZIVAGEPQU-UHFFFAOYSA-N 3-(4-methoxyphenyl)-8-[6-(methylamino)pyridin-3-yl]-1-pentan-2-yl-7H-purine-2,6-dione Chemical compound C(CC)C(C)N1C(=O)N(C=2N=C(NC=2C1=O)C=1C=NC(=CC=1)NC)C1=CC=C(C=C1)OC QRAJFZIVAGEPQU-UHFFFAOYSA-N 0.000 claims 1
- HXCINFYZZQPUQQ-UHFFFAOYSA-N 3-(4-methoxyphenyl)-8-[6-[(2-oxo-2-pyridin-3-ylethyl)amino]pyridin-3-yl]-1-pentan-2-yl-7H-purine-2,6-dione Chemical compound C(CC)C(C)N1C(=O)N(C=2N=C(NC=2C1=O)C=1C=NC(=CC=1)NCC(C1=CN=CC=C1)=O)C1=CC=C(C=C1)OC HXCINFYZZQPUQQ-UHFFFAOYSA-N 0.000 claims 1
- IWIRXFKTHJBLGG-UHFFFAOYSA-N 3-cyclopropyl-1-ethyl-8-[6-(2-methoxyethylamino)pyridin-3-yl]-7h-purine-2,6-dione Chemical compound C1=2N=C(C=3C=NC(NCCOC)=CC=3)NC=2C(=O)N(CC)C(=O)N1C1CC1 IWIRXFKTHJBLGG-UHFFFAOYSA-N 0.000 claims 1
- AXOZBTRTVSIHCK-UHFFFAOYSA-N 3-cyclopropyl-1-ethyl-8-[6-(methylamino)pyridin-3-yl]-7h-purine-2,6-dione Chemical compound C1=2N=C(C=3C=NC(NC)=CC=3)NC=2C(=O)N(CC)C(=O)N1C1CC1 AXOZBTRTVSIHCK-UHFFFAOYSA-N 0.000 claims 1
- FXYPFFWMBSZGOL-UHFFFAOYSA-N 3-cyclopropyl-8-[6-(methylamino)pyridin-3-yl]-1-propyl-7h-purine-2,6-dione Chemical compound C1=2N=C(C=3C=NC(NC)=CC=3)NC=2C(=O)N(CCC)C(=O)N1C1CC1 FXYPFFWMBSZGOL-UHFFFAOYSA-N 0.000 claims 1
- SPEBTNIPAFIDPC-UHFFFAOYSA-N 3-methyl-8-[6-(methylamino)pyridin-3-yl]-1-prop-2-ynyl-7h-purine-2,6-dione Chemical compound C1=NC(NC)=CC=C1C(N1)=NC2=C1C(=O)N(CC#C)C(=O)N2C SPEBTNIPAFIDPC-UHFFFAOYSA-N 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- GGFYNCWNVSRNQN-UHFFFAOYSA-N 7-(2-bromoethyl)-8-(6-chloropyridin-3-yl)-1,3-dipropylpurine-2,6-dione Chemical compound BrCCN1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(Cl)N=C1 GGFYNCWNVSRNQN-UHFFFAOYSA-N 0.000 claims 1
- DVRPSYMPOGXTNQ-UHFFFAOYSA-N 8-(2,6-dichloropyridin-3-yl)-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(Cl)N=C1Cl DVRPSYMPOGXTNQ-UHFFFAOYSA-N 0.000 claims 1
- YFZKDPFJCYQWAX-UHFFFAOYSA-N 8-(6-bromopyridin-3-yl)-1,3-diethyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1C1=CC=C(Br)N=C1 YFZKDPFJCYQWAX-UHFFFAOYSA-N 0.000 claims 1
- HVSDJXOTPGRMDE-UHFFFAOYSA-N 8-(6-bromopyridin-3-yl)-1,3-dimethyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(C)C(=O)N(C)C=2N=C1C1=CC=C(Br)N=C1 HVSDJXOTPGRMDE-UHFFFAOYSA-N 0.000 claims 1
- RWCGREFAXNNUOP-UHFFFAOYSA-N 8-(6-bromopyridin-3-yl)-3-methyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)NC(=O)N(C)C=2N=C1C1=CC=C(Br)N=C1 RWCGREFAXNNUOP-UHFFFAOYSA-N 0.000 claims 1
- VXUBRKBECGMJLK-UHFFFAOYSA-N 8-(6-chloropyridin-3-yl)-1,3-diethyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1C1=CC=C(Cl)N=C1 VXUBRKBECGMJLK-UHFFFAOYSA-N 0.000 claims 1
- ABZRXSOSKNAONT-UHFFFAOYSA-N 8-(6-chloropyridin-3-yl)-1-(3-fluoropropyl)-3,7-dihydropurine-2,6-dione Chemical compound FCCCN1C(=O)NC=2N=C(NC2C1=O)C=1C=NC(=CC1)Cl ABZRXSOSKNAONT-UHFFFAOYSA-N 0.000 claims 1
- SWVHDVTVWJZLCE-UHFFFAOYSA-N 8-(6-chloropyridin-3-yl)-1-propyl-3-prop-2-ynyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CC#C)C=2N=C1C1=CC=C(Cl)N=C1 SWVHDVTVWJZLCE-UHFFFAOYSA-N 0.000 claims 1
- AHRGRLCHURXYSA-UHFFFAOYSA-N 8-(6-chloropyridin-3-yl)-3-(4-methoxyphenyl)-1-pentan-2-yl-7H-purine-2,6-dione Chemical compound C(CC)C(C)N1C(=O)N(C=2N=C(NC=2C1=O)C=1C=NC(=CC=1)Cl)C1=CC=C(C=C1)OC AHRGRLCHURXYSA-UHFFFAOYSA-N 0.000 claims 1
- LTJPCVPDSNTQTL-UHFFFAOYSA-N 8-(6-chloropyridin-3-yl)-7-ethyl-1,3-dipropylpurine-2,6-dione Chemical compound CCN1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(Cl)N=C1 LTJPCVPDSNTQTL-UHFFFAOYSA-N 0.000 claims 1
- LEIZTQAPCJCIGA-UHFFFAOYSA-N 8-(6-chloropyridin-3-yl)-7-methyl-1,3-dipropylpurine-2,6-dione Chemical compound CN1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(Cl)N=C1 LEIZTQAPCJCIGA-UHFFFAOYSA-N 0.000 claims 1
- QPHLGOSAWIQSJO-UHFFFAOYSA-N 8-(6-piperidin-1-ylpyridin-3-yl)-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1N1CCCCC1 QPHLGOSAWIQSJO-UHFFFAOYSA-N 0.000 claims 1
- DHNDJKOEAQDJPD-UHFFFAOYSA-N 8-[2,6-bis(2-methoxyethyl)pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(CCOC)N=C1CCOC DHNDJKOEAQDJPD-UHFFFAOYSA-N 0.000 claims 1
- CCCPTSIOCKSGTQ-UHFFFAOYSA-N 8-[2,6-bis(methylamino)pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(NC)N=C1NC CCCPTSIOCKSGTQ-UHFFFAOYSA-N 0.000 claims 1
- JZXZWTFSLKREEI-UHFFFAOYSA-N 8-[2,6-bis[(2-oxo-2-pyridin-3-ylethyl)amino]pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C(=N1)NCC(=O)C=2C=NC=CC=2)=CC=C1NCC(=O)C1=CC=CN=C1 JZXZWTFSLKREEI-UHFFFAOYSA-N 0.000 claims 1
- YVMLHTYGOHBCGZ-UHFFFAOYSA-N 8-[2-chloro-6-(2-methoxyethylamino)pyridin-4-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC(Cl)=NC(NCCOC)=C1 YVMLHTYGOHBCGZ-UHFFFAOYSA-N 0.000 claims 1
- RDMGGJANVDQJIV-UHFFFAOYSA-N 8-[2-chloro-6-(methylamino)pyridin-4-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC(Cl)=NC(NC)=C1 RDMGGJANVDQJIV-UHFFFAOYSA-N 0.000 claims 1
- BHQUUGSUMICFPU-UHFFFAOYSA-N 8-[6-(1,4-diazepan-1-yl)pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1N1CCCNCC1 BHQUUGSUMICFPU-UHFFFAOYSA-N 0.000 claims 1
- YOIVNOQTNYHUPO-UHFFFAOYSA-N 8-[6-(2,2-diphenylethylamino)pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1NCC(C=1C=CC=CC=1)C1=CC=CC=C1 YOIVNOQTNYHUPO-UHFFFAOYSA-N 0.000 claims 1
- DFLYGAUEDKTJBE-UHFFFAOYSA-N 8-[6-(2-methoxyethyl)pyridin-3-yl]-3-methyl-7h-purine-2,6-dione Chemical compound C1=NC(CCOC)=CC=C1C(N1)=NC2=C1C(=O)NC(=O)N2C DFLYGAUEDKTJBE-UHFFFAOYSA-N 0.000 claims 1
- VTBPXOAZMUHOPB-UHFFFAOYSA-N 8-[6-(2-methoxyethylamino)pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(NCCOC)N=C1 VTBPXOAZMUHOPB-UHFFFAOYSA-N 0.000 claims 1
- BXQBOSMOYFLWHN-UHFFFAOYSA-N 8-[6-(3-methylpiperidin-1-yl)pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1N1CCCC(C)C1 BXQBOSMOYFLWHN-UHFFFAOYSA-N 0.000 claims 1
- ZROHZMPUZNRGSI-UHFFFAOYSA-N 8-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1N1CCN(C)CC1 ZROHZMPUZNRGSI-UHFFFAOYSA-N 0.000 claims 1
- BIQZUYHQALHZQS-UHFFFAOYSA-N 8-[6-(benzylamino)pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1NCC1=CC=CC=C1 BIQZUYHQALHZQS-UHFFFAOYSA-N 0.000 claims 1
- ZMTZGWJTWLYECU-UHFFFAOYSA-N 8-[6-(cyclohexylamino)pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1NC1CCCCC1 ZMTZGWJTWLYECU-UHFFFAOYSA-N 0.000 claims 1
- OFMGPQKZHNIOPM-UHFFFAOYSA-N 8-[6-(cyclopentylamino)pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1NC1CCCC1 OFMGPQKZHNIOPM-UHFFFAOYSA-N 0.000 claims 1
- QZWYFQZRNPSEPZ-UHFFFAOYSA-N 8-[6-(cyclopropylamino)pyridin-3-yl]-1,3-diethyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1C(C=N1)=CC=C1NC1CC1 QZWYFQZRNPSEPZ-UHFFFAOYSA-N 0.000 claims 1
- MFZLADREUMQWBO-UHFFFAOYSA-N 8-[6-(cyclopropylmethylamino)pyridin-3-yl]-1,3-diethyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1C(C=N1)=CC=C1NCC1CC1 MFZLADREUMQWBO-UHFFFAOYSA-N 0.000 claims 1
- UKYSCFDLWQDFHM-UHFFFAOYSA-N 8-[6-(furan-2-ylmethylamino)pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1NCC1=CC=CO1 UKYSCFDLWQDFHM-UHFFFAOYSA-N 0.000 claims 1
- FQNDDLGLHZNNAJ-UHFFFAOYSA-N 8-[6-(pentan-3-ylamino)pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(NC(CC)CC)N=C1 FQNDDLGLHZNNAJ-UHFFFAOYSA-N 0.000 claims 1
- RALCESMVPOPJOZ-UHFFFAOYSA-N 8-[6-[(2-hydroxy-2-phenylethyl)amino]pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1NCC(O)C1=CC=CC=C1 RALCESMVPOPJOZ-UHFFFAOYSA-N 0.000 claims 1
- FXQFULBXCYQFPU-UHFFFAOYSA-N 8-[6-[(2-methoxyphenyl)methylamino]pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1NCC1=CC=CC=C1OC FXQFULBXCYQFPU-UHFFFAOYSA-N 0.000 claims 1
- TUIJGAPHZLJUDI-UHFFFAOYSA-N 8-[6-[(2-methylphenyl)methylamino]pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1NCC1=CC=CC=C1C TUIJGAPHZLJUDI-UHFFFAOYSA-N 0.000 claims 1
- MVTNZBGCFDIGRY-UHFFFAOYSA-N 8-[6-[(2-oxo-2-pyridin-3-ylethyl)amino]pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1NCC(=O)C1=CC=CN=C1 MVTNZBGCFDIGRY-UHFFFAOYSA-N 0.000 claims 1
- HDYLXXLPNCGAKN-OLZOCXBDSA-N 8-[6-[(2s,5r)-2,5-dimethylpiperazin-1-yl]pyridin-3-yl]-1,3-diethyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1C(C=N1)=CC=C1N1C[C@@H](C)NC[C@@H]1C HDYLXXLPNCGAKN-OLZOCXBDSA-N 0.000 claims 1
- AFCWVRSOHCYSRQ-UHFFFAOYSA-N 8-[6-[(3-methoxyphenyl)methylamino]pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1NCC1=CC=CC(OC)=C1 AFCWVRSOHCYSRQ-UHFFFAOYSA-N 0.000 claims 1
- XBOFEUPHLAXDSP-UHFFFAOYSA-N 8-[6-[(4-methoxyphenyl)methylamino]pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1NCC1=CC=C(OC)C=C1 XBOFEUPHLAXDSP-UHFFFAOYSA-N 0.000 claims 1
- ZNLBTZMIODYOAY-UHFFFAOYSA-N 8-[6-[2-(3,4-dimethoxyphenyl)ethylamino]pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1NCCC1=CC=C(OC)C(OC)=C1 ZNLBTZMIODYOAY-UHFFFAOYSA-N 0.000 claims 1
- QXNRKUQYMAGDHX-UHFFFAOYSA-N 8-[6-[2-(4-methoxyphenyl)ethylamino]pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1NCCC1=CC=C(OC)C=C1 QXNRKUQYMAGDHX-UHFFFAOYSA-N 0.000 claims 1
- BQRJONNWICMYSA-UHFFFAOYSA-N 8-[6-[[2-(6-chloropyridin-3-yl)-2-oxoethyl]amino]pyridin-3-yl]-1,3-diethyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1C(C=N1)=CC=C1NCC(=O)C1=CC=C(Cl)N=C1 BQRJONNWICMYSA-UHFFFAOYSA-N 0.000 claims 1
- MGJXYCDMZLASBM-UHFFFAOYSA-N 8-[6-[[2-(6-chloropyridin-3-yl)-2-oxoethyl]amino]pyridin-3-yl]-3-(4-methoxyphenyl)-1-pentan-2-yl-7H-purine-2,6-dione Chemical compound C(CC)C(C)N1C(=O)N(C=2N=C(NC=2C1=O)C=1C=NC(=CC=1)NCC(C1=CN=C(C=C1)Cl)=O)C1=CC=C(C=C1)OC MGJXYCDMZLASBM-UHFFFAOYSA-N 0.000 claims 1
- YQIOUYLFRGXANI-UHFFFAOYSA-N 8-[6-[[2-oxo-2-[6-(trifluoromethyl)pyridin-3-yl]ethyl]amino]pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1NCC(=O)C1=CC=C(C(F)(F)F)N=C1 YQIOUYLFRGXANI-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims 1
- 229960005305 adenosine Drugs 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000008485 antagonism Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 125000005956 isoquinolyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000005493 quinolyl group Chemical group 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- IKWDLRGGUNRQAW-UHFFFAOYSA-N CC(C1)(C=C(CCC2)CC12O)NC Chemical compound CC(C1)(C=C(CCC2)CC12O)NC IKWDLRGGUNRQAW-UHFFFAOYSA-N 0.000 description 1
- FEWHVBXCYORMPQ-UHFFFAOYSA-N CC1CNC(CNC)C1 Chemical compound CC1CNC(CNC)C1 FEWHVBXCYORMPQ-UHFFFAOYSA-N 0.000 description 1
- HRLBSWFFGVIFIW-UHFFFAOYSA-N CN1C(C2)CNCC2C1 Chemical compound CN1C(C2)CNCC2C1 HRLBSWFFGVIFIW-UHFFFAOYSA-N 0.000 description 1
- GXIMUJOQZCMEFY-UHFFFAOYSA-N CN1C(CC2)CNC2C1 Chemical compound CN1C(CC2)CNC2C1 GXIMUJOQZCMEFY-UHFFFAOYSA-N 0.000 description 1
- YMTUWYHKZORWRX-UHFFFAOYSA-N CN1C(CC2)CNCC2C1 Chemical compound CN1C(CC2)CNCC2C1 YMTUWYHKZORWRX-UHFFFAOYSA-N 0.000 description 1
- RNIJSZGJNGTOTB-UHFFFAOYSA-N CNC1C(CC2)CC2C1 Chemical compound CNC1C(CC2)CC2C1 RNIJSZGJNGTOTB-UHFFFAOYSA-N 0.000 description 1
- UWBYHCLTULMDDX-UHFFFAOYSA-N CNC1C(CC2)CCN2C1 Chemical compound CNC1C(CC2)CCN2C1 UWBYHCLTULMDDX-UHFFFAOYSA-N 0.000 description 1
- LPNBBFKOUUSUDB-UHFFFAOYSA-N Cc(cc1)ccc1C(O)=O Chemical compound Cc(cc1)ccc1C(O)=O LPNBBFKOUUSUDB-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49787503P | 2003-08-25 | 2003-08-25 | |
| US60/497,875 | 2003-08-25 | ||
| PCT/US2004/027133 WO2005021548A2 (en) | 2003-08-25 | 2004-08-20 | Substituted 8-heteroaryl xanthines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007503443A JP2007503443A (ja) | 2007-02-22 |
| JP2007503443A5 true JP2007503443A5 (cg-RX-API-DMAC7.html) | 2007-06-14 |
| JP4769721B2 JP4769721B2 (ja) | 2011-09-07 |
Family
ID=34272616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006524755A Expired - Lifetime JP4769721B2 (ja) | 2003-08-25 | 2004-08-20 | 置換８−ヘテロアリールキサンチン |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US7342006B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP1658291B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4769721B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101222364B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN1894250B (cg-RX-API-DMAC7.html) |
| AR (1) | AR045499A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004268964B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0413922B8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2536553C (cg-RX-API-DMAC7.html) |
| DK (2) | DK1658291T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2440467T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL173723A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ545715A (cg-RX-API-DMAC7.html) |
| PL (1) | PL1658291T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1658291E (cg-RX-API-DMAC7.html) |
| RU (1) | RU2357969C2 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI362390B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005021548A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200602333B (cg-RX-API-DMAC7.html) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ556354A (en) * | 2001-10-01 | 2008-10-31 | Univ Virginia | 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof |
| US7317017B2 (en) * | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| NZ528591A (en) * | 2002-02-01 | 2006-11-30 | King Pharmaceuticals Res & Dev | 8-heteroaryl xanthine adenosine A2B receptor antagonists and their pharmaceutical use |
| EP1658291B1 (en) * | 2003-08-25 | 2013-10-02 | Dogwood Pharmaceuticals, Inc. | Substituted 8-heteroaryl xanthines |
| EP1778712B1 (en) * | 2004-08-02 | 2013-01-30 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
| CN101084212A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途 |
| TW200626155A (en) | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
| MX2007003332A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa. |
| AR051092A1 (es) * | 2004-09-20 | 2006-12-20 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa |
| EP1827438B2 (en) | 2004-09-20 | 2014-12-10 | Xenon Pharmaceuticals Inc. | Piperazin derivatives for inhibiting human stearoyl-coa-desaturase |
| BRPI0515482A (pt) | 2004-09-20 | 2008-07-22 | Xenon Pharmaceuticals Inc | derivados heterocìclicos e seus usos como agentes terapêuticos |
| EP2289510A1 (en) | 2004-09-20 | 2011-03-02 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
| JP5043668B2 (ja) | 2004-09-20 | 2012-10-10 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 複素環誘導体および治療薬としてのそれらの使用 |
| US7598379B2 (en) | 2005-02-25 | 2009-10-06 | Pgx Health, Llc | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines |
| WO2006091897A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Derivatives of 8-substituted xanthines |
| US7618962B2 (en) * | 2005-02-25 | 2009-11-17 | Pgx Health, Llc | Pyrazolyl substituted xanthines |
| GB0510141D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B3 |
| JP2009513563A (ja) | 2005-06-03 | 2009-04-02 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヒトのステアロイル−ＣｏＡデサチュラーゼ阻害剤としてのアミノチアゾール誘導体 |
| US7625881B2 (en) * | 2005-06-16 | 2009-12-01 | Gilead Palo Alto, Inc. | Prodrugs of A2B adenosine receptor antagonists |
| ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| EP1923388A4 (en) | 2005-08-12 | 2011-03-09 | Takeda Pharmaceutical | BRAIN / NEURONAL CELL PROTECTIVE AGENT AND THERAPEUTIC AGENT FOR SLEEP DISORDERS |
| US20070059740A1 (en) * | 2005-08-26 | 2007-03-15 | Linden Joel M | Method of targeting a2b adenosine receptor antagonist therapy |
| US7566401B2 (en) * | 2005-10-03 | 2009-07-28 | Kelm Mark A | Process for separating and isolating xanthines, individual polar protic monomers, and polar protic oligomers |
| ES2274712B1 (es) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
| US8178509B2 (en) * | 2006-02-10 | 2012-05-15 | University Of Virginia Patent Foundation | Method to treat sickle cell disease |
| GB0606774D0 (en) * | 2006-04-03 | 2006-05-10 | Novartis Ag | Organic compounds |
| US7884100B2 (en) * | 2006-06-16 | 2011-02-08 | Pgxhealth, Llc | Substituted 8-[6-amino-3-pyridyl]xanthines |
| CN101466382A (zh) | 2006-06-16 | 2009-06-24 | PGx健康有限责任公司 | 取代的8-[6-氨基-3-吡啶基]黄嘌呤 |
| US8188063B2 (en) * | 2006-06-19 | 2012-05-29 | University Of Virginia Patent Foundation | Use of adenosine A2A modulators to treat spinal cord injury |
| US8193200B2 (en) * | 2007-01-04 | 2012-06-05 | University Of Virginia Patent Foundation | Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease |
| RU2344137C1 (ru) * | 2007-07-18 | 2009-01-20 | Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА) | Производные 8-амино-7-(2-гидроксипропил-1)-1,3-диметилксантина гидрохлорида, проявляющие гемореологическую активность |
| US7875608B2 (en) * | 2007-12-17 | 2011-01-25 | Thompson Robert D | Substituted 8-[6-amino-3pyridyl]xanthines |
| CA2718983C (en) | 2008-03-26 | 2015-12-08 | Advinus Therapeutics Pvt. Ltd. | Heterocyclic compounds as adenosine receptor antagonist |
| EP2306838A4 (en) * | 2008-07-16 | 2011-12-14 | King Pharmaceuticals Res & Dev | METHOD FOR THE TREATMENT OF ATHEROSCLEROSIS |
| CA2755117C (en) | 2009-03-13 | 2018-09-11 | Advinus Therapeutics Private Limited | Substituted fused pyrimidine compounds |
| RU2404181C1 (ru) * | 2009-06-02 | 2010-11-20 | Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА) | 3-метил-8-пиперазино-7-(тиетанил-3)-1-этилксантина гидрохлорид, проявляющий антиагрегационную и дезагрегационную активность |
| WO2011005871A1 (en) | 2009-07-07 | 2011-01-13 | Pgxhealth, Llc | Substituted 8-[6-carbonylamine-3-pyridyl]xanthines as adenosine a2b antagonists |
| EP2499142B1 (en) | 2009-11-09 | 2016-09-21 | Advinus Therapeutics Limited | Substituted fused pyrimidine compounds, its preparation and uses thereof |
| EP2616470B1 (en) | 2010-09-13 | 2016-10-12 | Advinus Therapeutics Limited | Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications |
| EP2465859A1 (en) * | 2010-12-08 | 2012-06-20 | Life & Brain GmbH | 8-Triazolylxanthine derivatives, processes for their production and their use as adenosine receptor antagonists |
| CN102532137B (zh) * | 2011-12-05 | 2014-12-10 | 辽宁医学院 | 8-吡唑取代黄嘌呤类a2b腺苷受体拮抗剂及其合成方法和应用 |
| EP3389664A4 (en) | 2015-12-14 | 2020-01-08 | Raze Therapeutics Inc. | MTHFD2 CAFFEIN INHIBITORS AND USES THEREOF |
| WO2019018562A1 (en) | 2017-07-19 | 2019-01-24 | Ideaya Biosciences, Inc. | AMIDO COMPOUND AS MODULATORS OF AHR |
| WO2021194623A1 (en) * | 2020-03-26 | 2021-09-30 | Inspyr Therapeutics, Inc. | 8-substituted diaryl xanthines as dual a 2a-a 2b antagonists |
| BR112023023996A2 (pt) * | 2021-05-18 | 2024-01-30 | Adovate Llc | Xantinas de piridil contendo amida cíclica como antagonistas de a2b |
| CN113262882B (zh) * | 2021-07-21 | 2021-09-17 | 北京矿冶研究总院 | 阳离子捕收剂、制备方法及在磷矿反浮选中的应用 |
| WO2024050825A1 (en) * | 2022-09-09 | 2024-03-14 | National Institute Of Biological Sciences, Beijing | Compounds as mlkl inhibitors |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| DE8817122U1 (de) * | 1988-12-22 | 1993-02-04 | Boehringer Ingelheim Kg, 55218 Ingelheim | Neue Xanthinderivate mit Adenosinantogenistischer Wirkung |
| JPH06102662B2 (ja) * | 1989-09-01 | 1994-12-14 | 協和醗酵工業株式会社 | キサンチン誘導体 |
| WO1999030715A1 (en) * | 1997-12-15 | 1999-06-24 | Kyowa Hakko Kogyo Co., Ltd. | Preventives/remedies for sleep disturbance |
| US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
| US6060481A (en) | 1998-05-28 | 2000-05-09 | The Penn State Research Foundation | Method for improving insulin sensitivity using an adenosine receptor antagonist |
| GB9817623D0 (en) * | 1998-08-13 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
| US6545002B1 (en) | 1999-06-01 | 2003-04-08 | University Of Virginia Patent Foundation | Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors |
| EP1234576B1 (en) * | 1999-10-29 | 2006-03-08 | Kyowa Hakko Kogyo Co., Ltd. | Pharmaceutical composition for eating disorders |
| AU2001238342A1 (en) * | 2000-02-17 | 2001-08-27 | Cv Therapeutics, Inc. | Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation |
| US6977300B2 (en) * | 2001-11-09 | 2005-12-20 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| KR100937620B1 (ko) * | 2001-11-09 | 2010-01-20 | 씨브이 쎄러퓨틱스, 인코포레이티드 | Ａ２ｂ 아데노신 수용체 길항제 |
| US7304070B2 (en) | 2001-11-09 | 2007-12-04 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US7317017B2 (en) * | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| NZ528591A (en) * | 2002-02-01 | 2006-11-30 | King Pharmaceuticals Res & Dev | 8-heteroaryl xanthine adenosine A2B receptor antagonists and their pharmaceutical use |
| US7034070B2 (en) * | 2002-09-27 | 2006-04-25 | Vincent Chuang | Arylalkyl aminofunctional silanes for epoxy laminates |
| US7148229B2 (en) * | 2003-02-19 | 2006-12-12 | Hoffman-La Roche Inc. | Sulfonamide substituted xanthine derivatives |
| EP1658291B1 (en) | 2003-08-25 | 2013-10-02 | Dogwood Pharmaceuticals, Inc. | Substituted 8-heteroaryl xanthines |
| KR101247528B1 (ko) | 2004-09-01 | 2013-04-15 | 길리애드 사이언시즈, 인코포레이티드 | Ａ２ｂ 아데노신 수용체 길항제를 사용하는 상처 치유 방법 |
| CN101039677A (zh) * | 2004-10-15 | 2007-09-19 | Cv医药有限公司 | 利用a2b腺苷受体拮抗剂预防和治疗气道重建及肺部炎症的方法 |
| US7618962B2 (en) * | 2005-02-25 | 2009-11-17 | Pgx Health, Llc | Pyrazolyl substituted xanthines |
| US7598379B2 (en) * | 2005-02-25 | 2009-10-06 | Pgx Health, Llc | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines |
| WO2006091897A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Derivatives of 8-substituted xanthines |
| US7601723B2 (en) * | 2005-02-25 | 2009-10-13 | Pgx Health, Llc | Pyridyl substituted xanthines |
| US7625881B2 (en) * | 2005-06-16 | 2009-12-01 | Gilead Palo Alto, Inc. | Prodrugs of A2B adenosine receptor antagonists |
| JP5250848B2 (ja) * | 2006-03-17 | 2013-07-31 | ギリアード サイエンシーズ， インコーポレイテッド | Ａ２ｂアデノシン受容体拮抗物質を用いる肝疾患の予防および処置の方法 |
| US7884100B2 (en) * | 2006-06-16 | 2011-02-08 | Pgxhealth, Llc | Substituted 8-[6-amino-3-pyridyl]xanthines |
| US7767685B2 (en) * | 2006-06-29 | 2010-08-03 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2B receptor antagonists |
| US7875608B2 (en) * | 2007-12-17 | 2011-01-25 | Thompson Robert D | Substituted 8-[6-amino-3pyridyl]xanthines |
| CA2718983C (en) * | 2008-03-26 | 2015-12-08 | Advinus Therapeutics Pvt. Ltd. | Heterocyclic compounds as adenosine receptor antagonist |
-
2004
- 2004-08-20 EP EP04781752.3A patent/EP1658291B1/en not_active Expired - Lifetime
- 2004-08-20 DK DK04781752.3T patent/DK1658291T3/da active
- 2004-08-20 ES ES04781752.3T patent/ES2440467T3/es not_active Expired - Lifetime
- 2004-08-20 DK DK10012271.2T patent/DK2295434T3/en active
- 2004-08-20 BR BRPI0413922A patent/BRPI0413922B8/pt not_active IP Right Cessation
- 2004-08-20 AU AU2004268964A patent/AU2004268964B2/en not_active Ceased
- 2004-08-20 ES ES10012271.2T patent/ES2557310T3/es not_active Expired - Lifetime
- 2004-08-20 CA CA2536553A patent/CA2536553C/en not_active Expired - Lifetime
- 2004-08-20 NZ NZ545715A patent/NZ545715A/en not_active IP Right Cessation
- 2004-08-20 US US10/923,592 patent/US7342006B2/en not_active Expired - Lifetime
- 2004-08-20 EP EP10012271.2A patent/EP2295434B1/en not_active Expired - Lifetime
- 2004-08-20 CN CN2004800314554A patent/CN1894250B/zh not_active Expired - Fee Related
- 2004-08-20 JP JP2006524755A patent/JP4769721B2/ja not_active Expired - Lifetime
- 2004-08-20 RU RU2006109474/04A patent/RU2357969C2/ru active
- 2004-08-20 CN CN2010101556967A patent/CN101851238B/zh not_active Expired - Fee Related
- 2004-08-20 KR KR1020067003776A patent/KR101222364B1/ko not_active Expired - Fee Related
- 2004-08-20 PT PT47817523T patent/PT1658291E/pt unknown
- 2004-08-20 WO PCT/US2004/027133 patent/WO2005021548A2/en not_active Ceased
- 2004-08-20 PL PL04781752T patent/PL1658291T3/pl unknown
- 2004-08-25 AR ARP040103058A patent/AR045499A1/es not_active Application Discontinuation
- 2004-08-26 TW TW093125436A patent/TWI362390B/zh not_active IP Right Cessation
-
2006
- 2006-02-14 IL IL173723A patent/IL173723A/en active IP Right Grant
- 2006-03-22 ZA ZA200602333A patent/ZA200602333B/en unknown
-
2007
- 2007-12-14 US US11/956,876 patent/US7732455B2/en not_active Expired - Lifetime
-
2010
- 2010-04-19 US US12/762,711 patent/US20100273780A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007503443A5 (cg-RX-API-DMAC7.html) | ||
| RU2006109474A (ru) | Замещенные 8-гетероарилксантины | |
| AU761694B2 (en) | QT dispersion and heart rate variability improvement with CRF antagonists to prevent sudden death | |
| EP3877376B1 (en) | Pyridazinone compounds and uses thereof | |
| CA2189830C (en) | Uses for corticotropin releasing factor atagonists | |
| JP2021120403A (ja) | 一過性受容体電位ａ１イオンチャネルの阻害 | |
| CA2290766C (en) | Method of treating nitrate-induced tolerance | |
| RU2018138050A (ru) | Производные тиазолопиридина как агонисты gpr119 | |
| JP2019535664A5 (cg-RX-API-DMAC7.html) | ||
| CA2515197A1 (en) | Pyrazolopyridine derivates | |
| CA2644841C (en) | Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia | |
| RU2018138047A (ru) | Гетероциклические вещества - агонисты gpr119 | |
| KR20060110006A (ko) | 비전형 항정신병제와 코르티코트로핀 방출 인자 길항제의치료적 조합물 | |
| HRP20192151T1 (hr) | Derivati izokromena kao inhibitori fosfoinozitid 3-kinaza | |
| JP2016537384A5 (cg-RX-API-DMAC7.html) | ||
| JP2019530708A5 (cg-RX-API-DMAC7.html) | ||
| CN101043889B (zh) | A2b腺苷受体拮抗剂在制备促使伤口愈合的药物中的应用 | |
| JPWO2020052631A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2020239953A5 (cg-RX-API-DMAC7.html) | ||
| RU2021138377A (ru) | Производные пиридопиримидинов в качестве ингибиторов p2x3 | |
| HK40057226B (en) | Pyridazinone compounds and uses thereof | |
| HK40057226A (en) | Pyridazinone compounds and uses thereof | |
| JPWO2002019975A1 (ja) | 育毛剤 | |
| HK1241285A1 (en) | Inhibiting the transient receptor potential a1 ion channel |